Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Goldman Sachs Upgrades NIO (NIO) to Buy
- IBM misses Q2 targets as mainframe and software sales disappoint
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Aegis Capital Adjusts PT on Stemline (STML) to $55 Following Financing, Development Update
January 30, 2015 9:49 AM ESTAegis Capital lowers its price target on Stemline Therapeutics (Nasdaq: STML) from $68 to $55 and maintains a Buy rating on the stock following a recent financing round and development update.
Analyst Yi Chen commented, Stemline Therapeutics recently announced that it had licensed from... More
Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment
January 30, 2015 8:43 AM ESTStemline Therapeutics (NASDAQ: STML) announced that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that... More
